Blog
RSS FeedPosted by Michael Wonder on 03 Feb 2022
Addressing uncertainty in relative effectiveness assessments by HTA organisations
31 January 2022 - This study outlines the ways in which different health technology assessment organizations deal with uncertainty in relative ...
Posted by Michael Wonder on 02 Feb 2022
Understanding innovation of health technology assessment methods: the IHTAM framework
31 January 2022 - Adequate methods are urgently needed to guarantee the good practice of health technology assessment for technologies with ...
Posted by Michael Wonder on 02 Feb 2022
Olaparib a 'no go' for patients with breast cancer in England
2 February 2022 - Olaparib has been approved to treat patients with BRCA mutation positive HER2 negative metastatic breast cancer after ...
Posted by Michael Wonder on 02 Feb 2022
ABPI analysis on NICE’s changes for evaluating new medicines: next steps
31 January 2022 - NICE has published a new Manual, which sets out how the latest medicines and health technologies ...
Posted by Michael Wonder on 02 Feb 2022
Equity in cancer drug access in the UK
1 February 2022 - In draft guidance published on 5 January 2022, NICE announced their decision not to recommend the use ...
Posted by Michael Wonder on 31 Jan 2022
NICE publishes new combined methods and processes manual and topic selection manual for its health technology evaluation programmes
31 January 2022 - Changes to the way medicines and other health technologies are evaluated by NICE have now been incorporated ...
Posted by Michael Wonder on 24 Jan 2022
Patients to receive new cancer drugs faster under Brexit rules shake-up
23 January 2022 - Seven medicines already approved as changes cut as much as a month off approval times. ...
Posted by Michael Wonder on 20 Jan 2022
NICE moves: increased accessibility and flexibility for health tech
19 January 2022 - NICE also aims to make strides in digital, genomic and antimicrobial technologies ...
Posted by Michael Wonder on 20 Jan 2022
NICE signals commitment to greater flexibility in its evaluation of promising new health technologies and making patient access fairer
20 January 2022 - Changes to the way medicines and other health technologies are evaluated by NICE for use in the ...
Posted by Michael Wonder on 19 Jan 2022
UK’s NICE to launch sweeping changes to drug assessments to be faster, more agile
19 January 2022 - The health technology assessment body has been under pressure from drugmakers and patient groups for years to ...
Posted by Michael Wonder on 14 Jan 2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
11 January 2022 - The new CHEERS 2022 statement replaces previous CHEERS reporting guidance. ...
Posted by Michael Wonder on 11 Jan 2022
NICE recommends Rinvoq for psoriatic arthritis patients
10 January 2022 - The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination recommending ...
Posted by Michael Wonder on 07 Jan 2022
NICE recommends MSD’s Keytruda in combination with chemotherapy for routine treatment of lung cancer
7 January 2022 - With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer ...
Posted by Michael Wonder on 26 Dec 2021
Children and young people set to benefit from new treatment for peanut allergy
23 December 2021 - Children and young people aged between 4 and 17 with a peanut allergy could be set to ...
Posted by Michael Wonder on 20 Dec 2021
Biased Outcome reporting Guidelines for Underwhelming Studies (BOGUS) statement and checklist
10 December 2021 - A light hearted article to end the year. Merry Christmas to all our readers. We will ...